Neathera

Neathera is a clinical-stage biotechnology company focused on designing and accelerating the development of next-generation antibody therapies for autoimmune and inflammatory diseases. The company leverages its integrated CMC-to-Clinical Accelerator platform, which combines AI-assisted antibody engineering, predictive developability assessment, and process development to de-risk biologics and shorten the timeline from discovery to clinical validation. Neathera's lead clinical asset, EA5, is a long-acting subcutaneous humanized anti-C5 monoclonal antibody currently in Phase I clinical trials for paroxysmal nocturnal hemoglobinuria (PNH), generalized myasthenia gravis (gMG), and antiphospholipid syndrome (APS). The company's broader pipeline also includes preclinical programs targeting the IL-1 and RIP1/3 pathways.